Banque Pictet & Cie SA Boosts Stake in iShares Biotechnology ETF (NASDAQ:IBB)

Banque Pictet & Cie SA grew its stake in iShares Biotechnology ETF (NASDAQ:IBB) by 26.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 8,690 shares of the financial services provider’s stock after buying an additional 1,800 shares during the period. Banque Pictet & Cie SA’s holdings in iShares Biotechnology ETF were worth $1,149,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Huntington National Bank raised its holdings in shares of iShares Biotechnology ETF by 17.9% in the third quarter. Huntington National Bank now owns 1,054 shares of the financial services provider’s stock worth $153,000 after buying an additional 160 shares during the last quarter. National Bank of Canada FI raised its holdings in shares of iShares Biotechnology ETF by 5.9% during the third quarter. National Bank of Canada FI now owns 4,124 shares of the financial services provider’s stock worth $600,000 after purchasing an additional 229 shares during the last quarter. Avior Wealth Management LLC raised its holdings in shares of iShares Biotechnology ETF by 438.2% during the third quarter. Avior Wealth Management LLC now owns 3,229 shares of the financial services provider’s stock worth $470,000 after purchasing an additional 2,629 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund raised its holdings in shares of iShares Biotechnology ETF by 32.9% during the third quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 663,000 shares of the financial services provider’s stock worth $96,533,000 after purchasing an additional 164,000 shares during the last quarter. Finally, Main Management ETF Advisors LLC raised its holdings in shares of iShares Biotechnology ETF by 2.5% during the third quarter. Main Management ETF Advisors LLC now owns 593,370 shares of the financial services provider’s stock worth $86,395,000 after purchasing an additional 14,535 shares during the last quarter. Hedge funds and other institutional investors own 62.45% of the company’s stock.

iShares Biotechnology ETF Price Performance

Shares of iShares Biotechnology ETF stock opened at $136.55 on Friday. The firm has a fifty day moving average price of $135.73 and a 200 day moving average price of $141.03. iShares Biotechnology ETF has a 1 year low of $123.60 and a 1 year high of $150.57.

iShares Biotechnology ETF Cuts Dividend

The firm also recently announced a dividend, which was paid on Friday, December 20th. Investors of record on Tuesday, December 17th were issued a dividend of $0.0624 per share. The ex-dividend date of this dividend was Tuesday, December 17th.

iShares Biotechnology ETF Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.